Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot?

• Published in: Frontiers in immunology Vol. 12; p. 716342
• Main Authors: Køstner, Anne Helene, Nielsen, Patricia Switten, Georgsen, Jeanette Baehr, Parner, Erik Thorlund, Nielsen, Mette Bak, Kersten, Christian, Steiniche, Torben
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 31.08.2021
• Subjects: Aged; Aged, 80 and over; Biomarkers; C-reactive protein; C-Reactive Protein - metabolism; colon cancer; Colonic Neoplasms - complications; Colonic Neoplasms - metabolism; Colonic Neoplasms - pathology; Colonic Neoplasms - surgery; Female; Humans; Immunohistochemistry; Immunology; Inflammation - complications; Inflammation - etiology; Inflammation - pathology; Lymphocytes, Tumor-Infiltrating - immunology; Lymphocytes, Tumor-Infiltrating - metabolism; Lymphocytes, Tumor-Infiltrating - pathology; Male; Microsatellite Instability; Middle Aged; multiplex; Myeloid Cells - immunology; Myeloid Cells - metabolism; Myeloid Cells - pathology; myeloid inflammation; Neoplasm Staging; Neutrophil Infiltration - genetics; Neutrophil Infiltration - immunology; Recurrence; systemic inflammation; Tumor Microenvironment - immunology; systemic inflammation; C-reactive protein; multiplex; colon cancer; spatial profiling; immunohistochemistry; neutrophils; myeloid inflammation
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2021.716342

Systemic inflammation measured by the acute-phase protein CRP associates with poor outcome across cancer types. In contrast, local tumor-associated inflammation, primarily evaluated by T-lymphocytes, correlates with favorable prognosis. Yet, little is known whether these two responses are related or opposing processes and why elevated CRP in relation to cancer is detrimental for clinical outcome. As proof of concept, we developed a platform combining multiplexed IHC and digital imaging, enabling a virtual readout of both lymphoid and myeloid immune markers and their spatial patterns in the primary tumors of resected stage II and III colon cancer (CC) patients with and without accompanying systemic inflammation. Twenty-one patients with elevated CRP (>30 mg/l) and 15 patients with low CRP (<10 mg/l) were included in the analyses. Whole slides from the primary tumors were stained for markers of adaptive (CD8+, CD4+, foxp3 regulatory T cells, CD20+ B cells) and innate (CD68+ macrophages, CD66b+ neutrophils) immunity and the immune checkpoint molecule PD-L1. Associations between individual immune markers, preoperative CRP values, mismatch repair status (MMR), and risk of recurrence or death were assessed. Unsupervised hierarchical clustering was used to explore whether distinct immune phenotypes were present. Tumors from systemically inflamed patients (CRP >30 mg/l) displayed significantly more myeloid features in terms of higher densities of CD66b+neutrophils (p = 0.001) and CD68+macrophages (p = 0.04) and less lymphoid features (lower CD8 T cell, p = 0.03, and foxp3 regulatory T cell densities, p = 0.03) regardless of MMR status. Additionally, systemically inflamed patients harbored lower mean distances between neutrophils and tumor cells within the TME. Intriguingly, microsatellite instable (MSI) tumor status correlated with systemic inflammation. However, using a combinatorial approach, we found that regardless of an adaptive composite score (compounded CD4+ and CD8+ T cells), a high innate score (CD66b+ neutrophils and CD68+ macrophages) associated significantly with elevated CRP. In conclusion, tumor-associated systemic inflammation correlated with a myeloid-dominated TME in a small cohort of resectable CC patients. Our data highlight the importance of a comprehensive immune classification of tumors including players of innate immunity and support a role for CRP as an informative biomarker of the immune response taking place at the tumor site.